Cancers (Aug 2022)
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices
- Inne Nauwelaers,
- Nele Laudus,
- Dieter Peeters,
- Balazs Acs,
- Carsten Denkert,
- Stefan Michiels,
- Hugo Horlings,
- Kalliopi P. Siziopikou,
- Scott Ely,
- Dimitrios Zardavas,
- Roberts Mustimbo,
- John Bartlett,
- Giuseppe Floris,
- Johan Hartman,
- Carolien H. M. van Deurzen,
- Dorien Ceusters,
- Els Dequeker,
- Roberto Salgado
Affiliations
- Inne Nauwelaers
- Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium
- Nele Laudus
- Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium
- Dieter Peeters
- CellCarta NV, 2610 Antwerp, Belgium
- Balazs Acs
- Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, 171 64 Stockholm, Sweden
- Carsten Denkert
- Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Baldingerstr. 1, 35043 Marburg, Germany
- Stefan Michiels
- Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, 94800 Villejuif, France
- Hugo Horlings
- Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
- Kalliopi P. Siziopikou
- Department of Pathology, Section of Breast Pathology, Northwestern University, Chicago, IL 60611, USA
- Scott Ely
- Translational Medicine, Bristol-Myers Squibb, Princeton, NJ 08540, USA
- Dimitrios Zardavas
- Oncology Clinical Development, Bristol-Myers Squibb, Princeton, NJ 08540, USA
- Roberts Mustimbo
- Translational Medicine, Bristol-Myers Squibb, Princeton, NJ 08540, USA
- John Bartlett
- Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Edinburgh EH4 2XR, UK
- Giuseppe Floris
- Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, University of Leuven, 3000 Leuven, Belgium
- Johan Hartman
- Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, 171 64 Stockholm, Sweden
- Carolien H. M. van Deurzen
- Department of Pathology, Erasmus Medical Center-Cancer Institute, 3015 GD Rotterdam, The Netherlands
- Dorien Ceusters
- Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium
- Els Dequeker
- Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Kapucijnenvoer 35d, 3000 Leuven, Belgium
- Roberto Salgado
- Department of Pathology, GZA-ZNA Hospitals, 2610 Antwerp, Belgium
- DOI
- https://doi.org/10.3390/cancers14153762
- Journal volume & issue
-
Vol. 14,
no. 15
p. 3762
Abstract
Increasing data suggests that an intact immune system is required for improvedoutcomes in patients with Human Epidermal Growth Factor Receptor 2 (HER2+) and Triple Negative Breast Cancer (TNBC) [...]
Keywords
